molecules of the month

BMS TYK2 inhibitor

first-in-class oral, allosteric TYK2 inhibitor

FDA-approved for moderate-to-severe plaque psoriasis

opt. + SBDD of in-house phenotypic HTS hit

deucravacitinib (BMS-986165, SOTYKTU)

Bristol Myers Squibb, New York, NY

4 mins read

Deucravacitinib (Sotyktu) is a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor, FDA-approved in September 2022 for moderate-to-severe plaque psoriasis. It is the first novel oral therapy for this indication in nearly 10 years, and is believed to potentially become the new standard of care. Deucravacitinib is the first de novo deuterated drug to be approved, and is considered to be a likely megablockbuster for BMS. It is only the second approved deuterated drug following the approval of deutetrabenazine in 2017.  Deucravacitinib’s target, TYK2, is one of four Janus kinases (JAKs) and regulates the signaling pathways of a wide range of proinflammatory cytokines such as IL-12, IL-23, and type I interferons (IFNα). Unlike the other JAKs, it acts upon select…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: